Assistant Professor of Medicine, Ohio State University
Hematology
Dr. Kristie A. Blum, MD
|
|
Give Review
Kristie Blum works in the field of Hematology. She attended University of Miami Miller School of Medicine. University of Miami Miller School of Medicine is ranked 45/0 in Research/PrimaryCare. She over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Kristie Blum is a published doctor as well. She has 74 publications published. The latest was: Theiler's virus growth in murine macrophage cell lines depends on the state of differentiation. She is registered with Medicare.
Publications
- Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic Leukemia.
- A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell Lymphoma (DLBCL).
- Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
- Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin Lymphoma in the modern era.
- How I treat relapsed classical Hodgkin Lymphoma after autologous stem cell transplant.
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell Lymphoma.
- Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic Leukemia (CLL).
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
- Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma.
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk Lymphoma.
- A phase 1/1b study of combined rituximab, bendamustine, and ibrutinib in patients with previously untreated and relapsed/refractory non-Hodgkin's Lymphoma.
- Impact of induction regimen and stem cell transplantation on outcomes in double-hit Lymphoma: a multicenter retrospective analysis.
- Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
- Ibrutinib in B-cell Lymphomas.
- Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin Lymphoma is associated with prolonged progression-free survival.
- Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Grou...
- PI3Kdelta Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic Lymphoma: an open-label, multicentre, phase 1b/2 trial.
- Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis.
- Targeting BTK with ibrutinib in relapsed or refractory mantle-cell Lymphoma.
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma.
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic Leukemia.
- Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell Lymphoma.
- A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol.
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Co...
- ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
- Outcome of patients with relapsed or refractory chronic lymphocytic Leukemia treated with flavopiridol: impact of genetic features.
- Evaluation and management of lymphoma and Leukemia in pregnancy.
- FTY720 increases CD74 expression and sensitizes mantle cell Lymphoma cells to milatuzumab-mediated cell death.
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin Lymphoma.
- Hodgkin Lymphoma.
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell Lymphoma.
- The role of phosphatidylinositol 3-kinase-{delta} in the immunomodulatory effects of lenalidomide in chronic lymphocytic Leukemia.
- Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic Leukemia and is effectively targeted by PCI-32765.
- Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular Lymphoma.
- Mantle cell Lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.
- Lenalidomide treatment promotes CD154 expression on CLL Cells and enhances production of antibodies by normal B Cells through a PI3-kinase-dependent pathway.
- Flavopiridol, fludarabine, and rituximab in mantle cell Lymphoma and indolent B-cell lymphoproliferative disorders.
- The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-Cell malignancies in vitro and in vivo.
- Upcoming diagnostic and therapeutic developments in classical Hodgkin's Lymphoma.
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell Lymphoma: CALGB 59909.
- Phase II study of flavopiridol in relapsed chronic lymphocytic Leukemia demonstrating high response rates in genetically high-risk disease.
- Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin Lymphomas.
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic Leukemia.
- Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell Lymphoma.
- Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in hum...
- Allogeneic hematopoietic stem cell transplantation for peripheral T cell Lymphomas; evidence of graft-versus-T cell Lymphoma effect.
- Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic Leukemia response criteria.
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocyt...
- Adult Burkitt Leukemia and lymphoma.
- Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's Lymphoma.
- Antibodies for the treatment of diffuse large cell Lymphoma.
- Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
- Treatment strategies in mantle cell Lymphoma.
- [Proximal row carpectomy: a motion-preserving procedure in the treatment of advanced carpal collapse].
- Theiler's virus growth in murine macrophage cell lines depends on the State of differentiation.
- Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.
- Hodgkin disease/Lymphoma.
- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic Leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
- Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast Cancer: a multi-in...
- Supraventricular tachyarrhythmias after hematopoietic stem Cell transplantation: incidence, risk factors and outcomes.
- Serious pulmonary toxicity in patients with Hodgkin's Lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F ...
- Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
- 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin''s Lymphoma.
- Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and Leukemia Group B protocol 50206.
- Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
- Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygel...
- Feasibility of allogeneic hematopoietic stem cell transplantation for follicular Lymphoma undergoing transformation to diffuse large B-cell Lymphoma.
- High-dose therapy and autologous stem cell transplantation for follicular Lymphoma undergoing transformation to diffuse large B-cell Lymphoma.
- Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin Lymphoma.
- Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.
- Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive Disease.
- Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin Lymphoma: dose-limiting myelosuppres...
Schools
University Of Miami School Of Medicine
University Va Va Health Scis Center
Vanderbilt University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Washington University -
Vanderbilt University -
University of Virginia -
University of Miami Miller School of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1811902679 | |
| NPPES Provider LastName | BLUM | |
| NPPES Provider FirstName | KRISTIE | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 183.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 7.1 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811902679 |
| Last Name Of The Provider | BLUM |
| First Name Of The Provider | KRISTIE |
| View All |
Similar Doctors
|
Dr. Mark S. Collins, MD |
|
|
Dr. Scott C. Blair, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nseobong I. Ntukidem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark L. Segal, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rachel M. Layman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sonia M. Abuzakhm, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary E. Wissel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sumithira Vasu, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sam L. Penza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine R. Exten, MD |
|
|
Dr. Ryan M. Carr, MD |
|
Dr. Maura L. Gillison, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joseph Markowitz, MD |
|
|
Dr. Steven J. Nicol, MD |
|
|
Dr. Sarah A. Wall, MD |